Last €32.41 EUR
Change Today -0.32 / -0.98%
Volume 93.7K
As of 6:17 AM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (SAZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/31/13 - €42.50
52 Week Low
04/15/14 - €27.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STADA ARZNEIMITTEL AG (SAZ)

Related News

No related news articles were found.

stada arzneimittel ag (SAZ) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel ag (SAZ) Details

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates primarily in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s primarily products include Phospholipide, a liver medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Enalapril, an ACE inhibitor; and Omeprazole, a stomach medicine. The Branded Products segment offers non-prescription products, such as Grippostad and Ladival. This segment’s products also comprise Apo-Go, a Parkinson medicine; Snup, a nasal preparation; Zaldiar, a pain medicine; Chondroxid for the treatment of degenerative joint diseases; and Ladival, a sun cream. The company has license and collaboration agreements with Gedeon Richter Plc for the development and marketing of biosimilar products for two monoclonal antibodies rituximab and optionally trastuzumab. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany.

10,113 Employees
Last Reported Date: 08/7/14
Founded in 1895

stada arzneimittel ag (SAZ) Top Compensated Officers

Chairman of the Executive Board and Chief Exe...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.4M
Chief Business Development & Central Services...
Total Annual Compensation: €844.6K
Compensation as of Fiscal Year 2013.

stada arzneimittel ag (SAZ) Key Developments

Stada-Arzneimittel AG Reports Group Earnings Results for the Six Months Ended June 2014; Re-Affirms Earnings Guidance for the Year 2014

Stada-Arzneimittel AG reported group earnings results for the six months ended June 2014. For the period, the group reported sales of €1,002.8 million compared to €966.8 million, operating profit of €121.2 million compared to €129.5 million, operating profit, adjusted of €152.2 million compared to €135.4 million, EBITDA, reported of €192.1 million compared to €183.4 million, EBITDA, adjusted of €208.3 million compared to €189.1 million, net income, reported of €66.8 million or €1.11 per share compared to €66.6 million or €1.12 per share, net income, adjusted of €90.1 million or €1.49 per share compared to €70.1 million or €1.18 per share for the last year. The executive board confirms the outlook for financial year 2014. According to this, STADA expects slight growth in group sales, adjusted EBITDA and adjusted net income. For the overall year, the company had a tax rate guidance of 26% to 28%. And on an adjusted basis, and at the moment, after the first six months, the company would assume that the tax rate on an adjusted basis will rather be at the lower end of these 26% to 28%, so roughly up to 25% to 26% on an adjusted basis.

Stada-Arzneimittel AG - Analyst/Investor Day

To discuss the company's successful brand product strategy

STADA AG Presents at 2014 Russian Pharmaceutical Forum, Jun-17-2014 02:55 PM

STADA AG Presents at 2014 Russian Pharmaceutical Forum, Jun-17-2014 02:55 PM. Venue: Corinthia Saint-Petersburu Hotel, 57 Nevskij Prospect, St. Petersburg, Russia. Speakers: Dmitriy Efimov, Senior Vice President for Russia, CIS and South East Europe.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAZ:GR €32.41 EUR -0.32

SAZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 656.00 GBp +2.00
Richter Gedeon Nyrt 4,121 +59.00
Impax Laboratories Inc $24.55 USD +0.02
Skyepharma PLC 311.00 GBp -2.00
Vernalis PLC 44.00 GBp -0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation SAZ Industry Range
Price/Earnings 15.3x
Price/Sales 0.9x
Price/Book 1.9x
Price/Cash Flow 15.2x
TEV/Sales 0.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at